209 related articles for article (PubMed ID: 23134440)
1. Masking and triggered unmasking of targeting ligands on liposomal chemotherapy selectively suppress tumor growth in vivo.
Bandekar A; Zhu C; Gomez A; Menzenski MZ; Sempkowski M; Sofou S
Mol Pharm; 2013 Jan; 10(1):152-60. PubMed ID: 23134440
[TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy following the intracellular and interstitial release of liposomal doxorubicin.
Bandekar A; Karve S; Chang MY; Mu Q; Rotolo J; Sofou S
Biomaterials; 2012 Jun; 33(17):4345-52. PubMed ID: 22429980
[TBL] [Abstract][Full Text] [Related]
3. The pH-dependent association with cancer cells of tunable functionalized lipid vesicles with encapsulated doxorubicin for high cell-kill selectivity.
Karve S; Bandekar A; Ali MR; Sofou S
Biomaterials; 2010 May; 31(15):4409-16. PubMed ID: 20189243
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous liposome membranes with pH-triggered permeability enhance the in vitro antitumor activity of folate-receptor targeted liposomal doxorubicin.
Mamasheva E; O'Donnell C; Bandekar A; Sofou S
Mol Pharm; 2011 Dec; 8(6):2224-32. PubMed ID: 21899300
[TBL] [Abstract][Full Text] [Related]
5. The use of pH-triggered leaky heterogeneities on rigid lipid bilayers to improve intracellular trafficking and therapeutic potential of targeted liposomal immunochemotherapy.
Karve S; Alaouie A; Zhou Y; Rotolo J; Sofou S
Biomaterials; 2009 Oct; 30(30):6055-64. PubMed ID: 19665223
[TBL] [Abstract][Full Text] [Related]
6. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer.
Moura V; Lacerda M; Figueiredo P; Corvo ML; Cruz ME; Soares R; de Lima MC; Simões S; Moreira JN
Breast Cancer Res Treat; 2012 May; 133(1):61-73. PubMed ID: 21805188
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo.
Obata Y; Tajima S; Takeoka S
J Control Release; 2010 Mar; 142(2):267-76. PubMed ID: 19861141
[TBL] [Abstract][Full Text] [Related]
8. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
9. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
Shmeeda H; Tzemach D; Mak L; Gabizon A
J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
[TBL] [Abstract][Full Text] [Related]
10. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
11. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous domains and membrane permeability in phosphatidylcholine-phosphatidic acid rigid vesicles as a function of pH and lipid chain mismatch.
Karve S; Bajagur Kempegowda G; Sofou S
Langmuir; 2008 Jun; 24(11):5679-88. PubMed ID: 18471003
[TBL] [Abstract][Full Text] [Related]
13. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.
Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q
J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502
[TBL] [Abstract][Full Text] [Related]
14. pH triggered doxorubicin delivery of PEGylated glycolipid conjugate micelles for tumor targeting therapy.
Hu FQ; Zhang YY; You J; Yuan H; Du YZ
Mol Pharm; 2012 Sep; 9(9):2469-78. PubMed ID: 22827551
[TBL] [Abstract][Full Text] [Related]
15. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.
Shroff K; Kokkoli E
Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611
[TBL] [Abstract][Full Text] [Related]
16. Sticky Patches on Lipid Nanoparticles Enable the Selective Targeting and Killing of Untargetable Cancer Cells.
Sempkowski M; Zhu C; Menzenski MZ; Kevrekidis IG; Bruchertseifer F; Morgenstern A; Sofou S
Langmuir; 2016 Aug; 32(33):8329-38. PubMed ID: 27468779
[TBL] [Abstract][Full Text] [Related]
17. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
18. Targeting combinations of liposomal drugs to both tumor vasculature cells and tumor cells for the treatment of HER2-positive breast cancer.
Hare JI; Moase EH; Allen TM
J Drug Target; 2013 Jan; 21(1):87-96. PubMed ID: 23039213
[TBL] [Abstract][Full Text] [Related]
19. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
He X; Na MH; Kim JS; Lee GY; Park JY; Hoffman AS; Nam JO; Han SE; Sim GY; Oh YK; Kim IS; Lee BH
Mol Pharm; 2011 Apr; 8(2):430-8. PubMed ID: 21222482
[TBL] [Abstract][Full Text] [Related]
20. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
Reynolds JG; Geretti E; Hendriks BS; Lee H; Leonard SC; Klinz SG; Noble CO; Lücker PB; Zandstra PW; Drummond DC; Olivier KJ; Nielsen UB; Niyikiza C; Agresta SV; Wickham TJ
Toxicol Appl Pharmacol; 2012 Jul; 262(1):1-10. PubMed ID: 22676972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]